Author Details

Turkina, A G

Issue Section Title File
Vol 79, No 7 (2004) Editorial Molecular-cytogenetic monitoring of different regimens of treatment
Vol 79, No 7 (2004) Editorial Prediction of interferon therapy efficacy in chronic myeloid leukemia according to histomorphological evidence
Vol 79, No 7 (2004) Editorial Glivek in therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome
Vol 81, No 7 (2009) Editorial Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosinkinases
Vol 81, No 7 (2009) Editorial Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
Vol 82, No 2 (2010) Editorial A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
Vol 85, No 7 (2013) Editorial Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects
Vol 86, No 7 (2014) Editorial Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009-2012 population-based study
Vol 86, No 7 (2014) Editorial Synchronous and metachronous myeloid and lymphoid tumors
Vol 87, No 12 (2015) Editorial FIP1L1-PDGFRА-positive myeloproliferative disease with eosinophilia: A rare case with multiple organ dysfunction and a response to tyrosine kinase inhibitor therapy
Vol 88, No 7 (2016) Editorial A rare case of myeloproliferative disease with t(8;13)(p11;q12) associated with eosinophilia and lymphadenopathy PDF
(Rus)
Vol 88, No 12 (2016) Editorial Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera PDF
(Rus)
Vol 89, No 12 (2017) Editorial Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy
Vol 78, No 8 (2003) Editorial Therapeutic efficacy of imatinibmesilate (glivek) in chronic phase of myeloid leukemia

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies